An interventional study of Antioxidant- and Nutrient-Rich Food-Based Nutrition Intervention in Air Pollution Exposure, Oxidative Stress and Airway Inflammation, sponsored by Georgia Southern University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Georgia Southern University · Not applicable, Interventional, and Prevention
This pilot clinical trial will evaluate the feasibility and potential health effects of a nutrition-based intervention among adults living in communities affected by air pollution near the Port of Savannah, Georgia. Participants will be assigned to either a nutrition intervention group or a control group. The intervention group will receive biweekly grocery deliveries emphasizing foods naturally rich in antioxidants and anti-inflammatory nutrients, including vitamins C and E, omega-3 fatty acids, and polyphenols. The control group will continue their usual dietary practices during the study period.
The study will evaluate whether the nutritional intervention is associated with changes in selected respiratory, oxidative stress, and cardiometabolic health indicators. Assessments will include fractional exhaled nitric oxide (FeNO) as a marker of airway inflammation, hydrogen peroxide (H₂O₂) in exhaled breath condensate as a marker of oxidative stress, systolic and diastolic blood pressure, resting heart rate, and glycated hemoglobin (HbA1c). Indoor concentrations of particulate matter (PM), nitrogen dioxide (NO₂), and ozone (O₃) will also be monitored to characterize participants' household air-pollution exposures. Measurements will be collected at baseline and at subsequent study assessments, as specified for each outcome. Findings from this pilot study will be used to evaluate feasibility, estimate changes in health outcomes, and inform the design of a larger clinical trial investigating nutritional approaches to potentially reduce health effects associated with air-pollution exposure.
Exposure to air pollution is associated with oxidative stress and inflammatory responses that may contribute to adverse respiratory and cardiovascular health effects. Nutritional factors may influence antioxidant defenses and inflammatory pathways; however, relatively little intervention research has examined whether improving dietary intake can modify biological responses among individuals experiencing ongoing environmental air-pollution exposures. This pilot clinical trial will investigate the feasibility and potential effects of a food-based nutritional intervention among adults residing in communities affected by air pollution near the Port of Savannah, Georgia.
The study will include 20 participants, who will be assigned to a nutrition intervention group or a control group according to the study's approved allocation procedure. Participants in the intervention group will receive biweekly grocery deliveries emphasizing foods naturally rich in antioxidant and anti-inflammatory dietary components, including vitamins C and E, omega-3 fatty acids, and polyphenols. Participants assigned to the control group will maintain their usual dietary practices during the active study period. Intervention feasibility and adherence will also be evaluated to inform the design and implementation of a future larger-scale trial.
Respiratory and oxidative-stress assessments will include fractional exhaled nitric oxide (FeNO), measured using a NIOX Mini device, and hydrogen peroxide (H₂O₂) measured in exhaled breath condensate collected using an RTube® collection system. Cardiometabolic assessments will include systolic and diastolic blood pressure and resting heart rate measured using a validated automatic upper-arm blood pressure monitor. HbA1c will be assessed at baseline and the final assessment as an exploratory measure of longer-term glycemic status. Indoor particulate matter (PM), nitrogen dioxide (NO₂), and ozone (O₃) will also be monitored to characterize household air-pollution exposures.
Study assessments will be performed at baseline and at subsequent study time points according to the protocol. Changes in respiratory, oxidative-stress, and cardiometabolic measures will be compared over time and between study groups. Because this is a pilot study, the findings will primarily be used to evaluate study feasibility, intervention adherence, outcome variability, and preliminary effect estimates rather than to establish definitive clinical efficacy. The results will provide information needed to refine the intervention, outcome-selection strategy, and study procedures and to estimate parameters needed for the design of a larger clinical trial.
Georgia Southern University is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the nutrition intervention group will receive biweekly grocery deliveries emphasizing foods naturally rich in antioxidant and anti-inflammatory dietary components, including vitamins C and E, omega-3 fatty acids, and polyphenols. Participants will receive guidance on incorporating the provided foods into their usual diet throughout the intervention period. Respiratory, oxidative-stress, cardiometabolic, and environmental exposure measures will be assessed according to the study protocol.
Other: Antioxidant- and Nutrient-Rich Food-Based Nutrition Intervention
Participants assigned to the control group will continue their usual dietary practices during the active study period and will not receive the study grocery intervention during this period. The same study assessments will be conducted according to the study protocol to allow comparison of changes in health outcomes between the intervention and control groups.
Participants assigned to the intervention will receive biweekly grocery deliveries containing selected foods naturally rich in antioxidant and anti-inflammatory dietary components, including vitamins C and E, omega-3 fatty acids, and polyphenols. Participants will receive guidance on incorporating the provided foods into their usual dietary patterns. The intervention is designed to increase consumption of nutrient-rich foods and to evaluate the feasibility and potential effects of this dietary approach on respiratory inflammation, oxidative stress, and cardiometabolic outcomes among adults living in a community affected by air pollution.
Participant Retention Rate
Through the Final Assessment Participant retention will be assessed as the proportion of enrolled participants who complete the study through the final Week 12 assessment. Retention rate will be calculated as the number of enrolled participants who complete the final assessment, divided by the total number of participants enrolled at baseline, multiplied by 100. A retention rate of ≥80% will be considered evidence of acceptable feasibility for a future larger-scale trial.
Time frame: Baseline through Week 12.
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)
Fractional exhaled nitric oxide (FeNO) will be measured in parts per billion (ppb) using the NIOX Mini device as a non-invasive marker of airway inflammation. FeNO will be assessed using standardized procedures, and changes over time will be compared between the nutrition intervention and control groups.
Time frame: Baseline, approximately Week 6, and Week 12
Change From Baseline in Hydrogen Peroxide (H₂O₂) Concentration in Exhaled Breath Condensate
Hydrogen peroxide (H₂O₂) concentration in exhaled breath condensate (EBC) will be measured as a non-invasive marker of respiratory oxidative stress. EBC will be collected using the RTube® collection system, and H₂O₂ concentration will be quantified using the Amplex™ Red Hydrogen Peroxide/Peroxidase Assay with fluorescence detection. H₂O₂ concentrations will be reported in micromolar (µM) units. Changes from baseline will be evaluated over the intervention period and compared between the nutrition intervention and control groups.
Time frame: Baseline, approximately Week 6, and Week 12
Change From Baseline in Systolic Blood Pressure
Systolic blood pressure will be measured in millimeters of mercury (mmHg) using a validated automatic upper-arm blood pressure monitor. Participants will obtain two measurements approximately one minute apart after at least five minutes of seated rest, and the average of the two measurements will be used for analysis.
Time frame: Baseline, approximately Week 6, and Week 12
Change From Baseline in Diastolic Blood Pressure
Diastolic blood pressure will be measured in millimeters of mercury (mmHg) using a validated automatic upper-arm blood pressure monitor. Two measurements approximately one minute apart will be obtained after at least five minutes of seated rest, and the average will be used for analysis.
Time frame: Baseline, approximately Week 6, and Week 12
Change From Baseline in Resting Heart Rate
Resting heart rate will be measured in beats per minute (bpm) using a validated automatic upper-arm blood pressure monitor after the participant has rested quietly in a seated position for at least five minutes. Two resting heart rate measurements will be obtained approximately one minute apart, and the mean of the two measurements will be used as the resting heart rate value for each assessment.
Time frame: Baseline, approximately Week 6, and Week 12
Change From Baseline in Glycated Hemoglobin (HbA1c)
Glycated hemoglobin (HbA1c) will be measured using an FDA-cleared point-of-care finger-stick testing system as an exploratory marker of longer-term glycemic status. HbA1c will be reported as a percentage.
Time frame: Baseline and Week 12
Recruitment/Accrual Rate
Recruitment rate will be assessed as the proportion of individuals determined to be eligible for the study who enroll and complete the baseline assessment. The recruitment rate will be calculated as the number of eligible individuals enrolled divided by the total number of eligible individuals approached/invited to participate, multiplied by 100. Recruitment feasibility will be evaluated against a prespecified target of ≥70% enrollment of eligible individuals.
Time frame: From initiation of recruitment through completion of study enrollment, approximately 6 months.
Adherence to the Food-Based Nutrition Intervention
Intervention adherence and fidelity will be evaluated among participants assigned to the nutrition intervention group. Delivery fidelity will be assessed as the proportion of scheduled biweekly grocery deliveries successfully completed during the 12-week intervention. Participant adherence will be assessed using study records and participant-reported consumption of the targeted foods provided through the intervention. These measures will be used to determine whether the food-based nutrition intervention can be delivered as planned and followed by participants in preparation for a future larger-scale clinical trial.
Time frame: Throughout the 12-week intervention.
Plan to share: No — Individual participant-level data are not planned for external sharing because this is a small pilot community-based study and the combination of health, environmental exposure, and participant characteristics may increase the potential for participant re-identification. Aggregate study results will be disseminated through scientific presentations and peer-reviewed publications.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Apr 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Georgia Southern University